Table 1 Comparison of the total numbers of CTLA-4/mAb, CTLA-4/B7 and CD28/B7 complexes formed at the end of simulations performed with the different concentrations (= 0 μM, 10 μM and 15 μM) of ipilimumab and tremelimumab
From: A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions
Interactions | Number of interacting CTLA-4/CD28 monomers | |||||
|---|---|---|---|---|---|---|
Initial | Antibody =0 μM | Tremelimumab | Ipilimumab | |||
(10 μM) | (15 μM) | (10 μM) | (15 μM) | |||
CD28/B7–2 | 0 | 127 | 121 | 121 | 121 | 120 |
CD28/B7–1 | 0 | 54 | 83 | 84 | 77 | 81 |
CTLA-4/B7–2 | 0 | 8 | 17 | 12 | 40 | 32 |
CTLA-4/B7–1 | 0 | 790 | 20 | 11 | 129 | 60 |
CTLA-4/mAb | 0 | 0 | 763 | 778 | 631 | 707 |